What is the Solution?

Orakl Oncology is addressing the critical challenge of high drug failure rates in clinical trials, largely caused by inaccurate and disjointed decisions based on heterogeneous data and models that poorly translate to humans. In response to this challenge, Orakl has developed a first-in-class, AI-powered techbio platform that integrates real-world patient data with advanced biology into a unified decision-making engine for the entire drug development process. This innovative technology delivers best-in-class predictions, expected to augment the recruitment of responding patients by 50% and reduce clinical trial costs by threefold, transforming the oncology drug development landscape and accelerating the delivery of more effective drugs to patients.

Powered by hundreds of individualized patient avatars, Orakl’s platform combines longitudinal real-world data with sustainable tissues derived from the same patients, enabling precise simulations of real-life drug responses. By leveraging machine learning, advanced cell biology, and engineering, Orakl supports pharmaceutical and biotech companies in predicting and optimizing clinical trial outcomes, identifying and validating new therapeutic targets, and optimizing drug combinations. Initially focusing on colorectal and pancreatic cancers, the platform also informs in-licensing decisions and paves the way for Orakl to develop its own internal therapeutic pipeline, marking a significant leap forward in precision oncology.